1. Messenger A.G., McKillop J., Farrant P., McDonagh A.J., Sladden M. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. British Journal of Dermatology 2012; 166: 916-926.
2. Darwin E., Hirt P., Fertig R. et al. Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options. Int J Trichology. 2018 Mar-Apr; 10(2): 51 60.
3. Strazzulla L.C., Wang E. H. C., Avila L. et al. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018 Jan;78(1):1-12. doi: 10.1016/j.jaad.2017.04.1141.
4. Alkhalifah A. Alopecia areata update. Dermatol Clin. 2013; 31:93 108.
5. Brzezińska-Wcisło L., Bergler-Czop B., Wcisło-Dziadecka D., Lis-Święty A. New aspects of the treatment of alopecia areata. Postepy Dermatol Alergol. 2014; 31(4):262 265. doi:10.5114/pdia.2014.40923
6. Lee S., Lee Y. B., Kim B. J.et al. Screening of thyroid function and autoantibodies in patients with alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol 2019; 80:1410.
7. Lee S., Kim B. J., Lee C. H. et al. Increased prevalence of vitamin D deficiency in patients with alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2018 Jul; 32(7):1214-1221.
8. Almohanna H.M., Ahmed A. A., Tsatalis J. P. et al. The Role of Vitamins and Minerals in Hair Loss: A Review. Dermatol Ther (Heidelb). 2019 Mar; 9 (1): 51-70. doi: 10.1007/s13555-018-0278-6. Epub 2018 Dec 13.
9. Mahmoudi H., Salehi M., Moghadas S. et al. Dermoscopic findings in 126 patients with alopecia areata: A cross-sectional study. Int J Trichol 2018; 10:118-23.
10. Inui S., Nakajima T., Nakagawa K. et al. Clinical significance of dermoscopy in alopecia areata: analysis of 300 cases. Int J Dermatol. 2008; 47(7): 688.
11. Jain N., Doshi B., Khopkar U. Trichoscopy in alopecias: diagnosis simplified. Int J Trichology. 2013; 5 (4):170 178. doi:10.4103/0974-7753.130385
12. Kuty-Pachecka M. Psychological and psychopathological factors in alopecia areata. Psychiatr Pol. 2015; 49 (5): 955-64.
13. McCall W. V., Reboussin B. A., Cohen W. Subjective measurement of insomnia and quality of life in depressed inpatients. J Sleep Res.2000 Mar; 9(1):43-8.
14. Терещенко, Галина Павловна Клинико-морфологические особенности и нарушения местных иммунных реакций при гнездной алопеции с учетом стадий активности заболевания// авторефер. на соис. канд.мед наук., Москва, 2011 - 25с.
15. Meah N., Wall D., York K. et.al. The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020 Jul;83(1):123-130. doi: 10.1016/j.jaad.2020.03.004. Epub 2020 Mar 9. PMID: 32165196.
16. Joly P. The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. J Am Acad Dermatol 2006; 55: 632-636.
17. Phan K., Ramachandran V., Sebaratnam D.F. Methotrexate for alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol. 2019 Jan;80(1):120-127.e2. doi: 10.1016/j.jaad.2018.06.064. Epub 2018 Jul 10.
18. Nowaczyk J., Makowska K., Rakowska A. et al. Cyclosporine With and Without Systemic Corticosteroids in Treatment of Alopecia Areata: A Systematic Review. Dermatol Ther (Heidelb). 2020 Jun;10(3):387-399. doi: 10.1007/s13555-020-00370-2. Epub 2020 Apr 8. PMID: 32270396; PMCID: PMC7211785.
19. Deborah Lee, Doo Jin Oh et. al, Treatment of Severe Alopecia Areata: Combination Therapy Using Systemic Cyclosporine A with Low Dose Corticosteroids. Ann Dermatol. 2008 Dec; 20(4): 172 178. Published online 2008 Dec 31. doi: 10.5021/ad.2008.20.4.172
20. Aşkın Ö, Özkoca D, Uzunçakmak TK et.al. Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic. Dermatol Ther. 2021 Mar;34(2):e14746. doi: 10.1111/dth.14746.
21. Almutairi N., Nour T. M., Hussain N. H. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study. Dermatology. 2019; 235(2):130-136. doi: 10.1159/000494613. Epub 2018 Dec 19.
22. Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areataand variants in adolescents. J Am Acad Dermatol 2017;76:29e32.
23. Kubeyinje E. P. Intralesional triamcinolone acetonide in alopecia areata amongst 62 Saudi Arabs. East Afr Med J 1994; 71: 674-675.
24. Abell E., Munro D. D. Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol 1973; 88:55-59.
25. Shapiro J., Price V. H. Hair regrowth. Therapeutic agents. Dermatol Clin 1998: 16: 341-356.
26. Chang K. H, Rojhirunsakool S., Goldberg L. J. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol 2009: 8: 909-912.
27. Shapiro J., Madani S. Alopecia areata: Diagnosis and management. Int J Dermatol 1999; 38 (Suppl 1): 19-24.
28. Porter D., Burton J.L. A comparison of intra-lesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata. Br J Dermatol 1971; 85:272-273.
29. Gregoriou S., Kazakos С., Rigopoulos D. Treatment options for alopecia areata, Expert Review of Dermatology 2011, 6:5, 537-548.
30. Freire PCB, Riera R, Martimbianco A. et. al. Minoxidil for patchy alopecia areata: systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1792-1799. doi: 10.1111/jdv.15545. Epub 2019 Jun 28. PMID: 30835901.
31. Wang E, Lee JS, Tang M. Current treatment strategies in pediatric alopecia areata. Indian J Dermatol. 2012 Nov;57(6):459-65. doi: 10.4103/0019-5154.103066. PMID: 23248364; PMCID: PMC3519253.
32. Olsen E.A., Carson S.C., Turney E. A.. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992; 128(11): 1467-1473.
33. Pascher F., Kurtin S., Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of the ensuing localized acneform response. Dermatologica 1970; 141(3): 193-202.